Premium
Clinical experience with a new type of orally effective diuretic agent
Author(s) -
Seller Robert H.,
Fuchs Morton,
Onesti Gaddo,
Swartz Charles,
Brest Albert N.,
Moyer John H.
Publication year - 1962
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196232180
Subject(s) - benzothiadiazine , diuretic , hydrochlorothiazide , pharmacology , chemistry , potency , sulfonamide , medicine , in vitro , biochemistry , medicinal chemistry , stereochemistry , blood pressure
Of the newer diuretic agents, many are modifications of a benzothiadiazine molecule. Although a ring system (sulfur‐1, 1‐dioxide) is found in all of these benzothiadiazine drugs, it has been found that this ring is not essential for saluretic activity. A new type of drug, a member of the quinazolinone sulfonamide family (quinethazone), has been found to be a saluretic agent of the same order of potency as hydrochlorothiazide with regard to its natriuretic activity. The sodium and potassium excretion ratio is high. The duration of activity appears to be approximately 24 hours. Administration of quinethazone for 2 days induced an average Weight loss of more than 2 pounds in a group of 30 outpatients. A study of the same patients who previously had required two or more mercurial injections a week indicated that daily administration of quinethazone maintained them in an edema‐free state without significant toxic effects.